Stockhub

Algernon Pharmaceuticals Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 August 2022

11 August 2022

26 July 2022

  • curprev 15:1815:18, 26 July 2022‎ Chris talk contribs‎ 1,014 bytes +1,014‎ Created page with "Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Algernon_Pharmaceuticals_Inc.’